Safety and Efficacy Study of Topical Administration of FOV2304 (High Dose or Low Dose) for the Treatment of Center-involving Clinically Significant Macular Edema Associated With Diabetic Retinopathy
Public ClinicalTrials.gov record NCT01319487. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A 6-month, Phase II, Double-masked, Multicenter, Randomized, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Topical Administration of Two Concentrations of FOV2304 (High Dose or Low Dose) for the Treatment of Center-involving Clinically Significant Macular Edema Associated With Diabetic Retinopathy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of the study is to determine whether concentrations of FOV2304 (high dose or low dose) administered in the eye are more effective than placebo in treating patients with diabetic macular edema, following 12 weeks of treatment.
Study identification
- NCT ID
- NCT01319487
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 267 participants
Conditions and interventions
Conditions
Interventions
- 2304 Eye Drops High Dose Drug
- 2304 Eye Drops Low Dose Drug
- Placebo Eye Drops Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 2011 (Type not available)
- Primary completion
- Mar 2012 (Actual)
- Completion
- Jun 2012 (Actual)
- Last update posted
- Aug 23, 2012
2011 – 2012
United States locations
- U.S. sites
- 14
- U.S. states
- 11
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Center 1115 | Phoenix | Arizona | — | — |
| Center 1116 | Phoenix | Arizona | — | — |
| Center 1108 | Fort Myers | Florida | — | — |
| Center 1106 | Chicago | Illinois | — | — |
| Center 1105 | Indianapolis | Indiana | — | — |
| Center 1101 | Boston | Massachusetts | — | — |
| Center 1109 | Boston | Massachusetts | — | — |
| Center 1111 | Boston | Massachusetts | — | — |
| Center 1114 | Traverse | Michigan | — | — |
| Center 1112 | Toms River | New Jersey | — | — |
| Center 1107 | Lynbrook | New York | — | — |
| Center 1110 | Pittburgh | Pennsylvania | — | — |
| Center 1104 | Nashville | Tennessee | — | — |
| Center 1103 | San Antonio | Texas | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 51 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01319487, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 23, 2012 · Synced Oct 29, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01319487 live on ClinicalTrials.gov.